3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
12
Prostatic Neoplasms
5
Ovarian Neoplasms
4
Neoplasms
4
Advanced Solid Tumors
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrence
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumor
1
Interventions
Injections
24
pembrolizumab
13
toripalimab
12
tislelizumab
9
Gemcitabine
7
Cisplatin
7
Carboplatin
6
atezolizumab
5
Nivolumab
5
Irinotecan
5
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
trastuzumab deruxtecan
3
spartalizumab
3
cediranib
3
Paclitaxel
3
PM 01183
3
Capecitabine
3
sintilimab
2
olaparib
2
lenvatinib
2
glumetinib
2
camrelizumab
2
apatinib
2
Therapeutics
2
Midazolam
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Tumor
×
talazoparib
×
Clear all
NCT04497116
2025-10-21
TRESR
Repare Therapeutics
Phase 1/2
Completed
276 enrolled
33 charts